AR106477A1 - Combinación farmacéutica de antagonista del receptor nk3 y biguanidas - Google Patents
Combinación farmacéutica de antagonista del receptor nk3 y biguanidasInfo
- Publication number
- AR106477A1 AR106477A1 ARP160103263A ARP160103263A AR106477A1 AR 106477 A1 AR106477 A1 AR 106477A1 AR P160103263 A ARP160103263 A AR P160103263A AR P160103263 A ARP160103263 A AR P160103263A AR 106477 A1 AR106477 A1 AR 106477A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutically effective
- biguanides
- effective salts
- antagonist
- receptor antagonist
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 4
- 150000003839 salts Chemical class 0.000 abstract 4
- 229940123208 Biguanide Drugs 0.000 abstract 3
- 101001125071 Homo sapiens Neuromedin-K receptor Proteins 0.000 abstract 3
- 102100029409 Neuromedin-K receptor Human genes 0.000 abstract 3
- 150000004283 biguanides Chemical class 0.000 abstract 3
- 239000002464 receptor antagonist Substances 0.000 abstract 3
- 229940044551 receptor antagonist Drugs 0.000 abstract 3
- 230000002195 synergetic effect Effects 0.000 abstract 3
- QYTBBBAHNIWFOD-NRFANRHFSA-N pavinetant Chemical compound N([C@@H](CC)C=1C=CC=CC=1)C(=O)C(C1=CC=CC=C1N=1)=C(NS(C)(=O)=O)C=1C1=CC=CC=C1 QYTBBBAHNIWFOD-NRFANRHFSA-N 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- BIAVGWDGIJKWRM-FQEVSTJZSA-N 3-hydroxy-2-phenyl-n-[(1s)-1-phenylpropyl]quinoline-4-carboxamide Chemical group N([C@@H](CC)C=1C=CC=CC=1)C(=O)C(C1=CC=CC=C1N=1)=C(O)C=1C1=CC=CC=C1 BIAVGWDGIJKWRM-FQEVSTJZSA-N 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 abstract 1
- 229960003105 metformin Drugs 0.000 abstract 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 abstract 1
- 239000011885 synergistic combination Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Una composición sinérgica conformada por antagonista del receptor NK3 o sus sales farmacéuticamente efectivas, y biguanidas o sus sales farmacéuticamente efectivas, para el tratamiento de PCOS y trastornos relacionados. Combinación sinérgica que comprende combinaciones de un antagonista del receptor NK3 o sus sales farmacéuticamente efectivas, y biguanidas o sus sales farmacéuticamente efectivas en una composición farmacéutica en una sola unidad. Métodos para preparar dichas composiciones farmacéuticas por separado en forma de kit que contiene ambos agentes activos, y con métodos para tratar un sujeto con dicha composición. Reivindicación 2: La composición sinérgica de acuerdo con la reivindicación 1, caracterizada porque el antagonista del receptor NK3 se selecciona entre Talnetant (SB223412), AZD-4901 y AZD-2624. Reivindicación 3: La composición sinérgica de acuerdo con la reivindicación 1, caracterizada porque las biguanidas son Metformina.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN4102MU2015 | 2015-10-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR106477A1 true AR106477A1 (es) | 2018-01-17 |
Family
ID=57321359
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160103263A AR106477A1 (es) | 2015-10-29 | 2016-10-26 | Combinación farmacéutica de antagonista del receptor nk3 y biguanidas |
Country Status (3)
| Country | Link |
|---|---|
| AR (1) | AR106477A1 (es) |
| TW (1) | TW201729808A (es) |
| WO (1) | WO2017072629A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110840869A (zh) * | 2019-10-15 | 2020-02-28 | 四川大学华西第二医院 | 二甲双胍在子宫内膜异位症药物中的应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69531458T2 (de) | 1994-05-27 | 2004-08-05 | Glaxosmithkline S.P.A. | Chinolinderivate als tachykinin nk3 rezeptor antagonisten |
| EA002124B1 (ru) | 1995-11-24 | 2001-12-24 | Смитклайн Бичам С.П.А. | Производные хинолина |
| GB9524104D0 (en) | 1995-11-24 | 1996-01-24 | Smithkline Beecham Spa | Novel compounds |
| AR004735A1 (es) | 1995-11-24 | 1999-03-10 | Smithkline Beecham Spa | Quinoleina 4-amido sustituida, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y el uso de los mismos para lapreparacion de un medicamento. |
| GB9524137D0 (en) | 1995-11-24 | 1996-01-24 | Smithkline Beecham Spa | Novel compounds |
| CO5150149A1 (es) | 1998-11-20 | 2002-04-29 | Smithkline Beecham Spa | Composiciones farmaceuticas derivadas de quinolina |
| EP1146873B1 (en) * | 1999-01-25 | 2005-03-16 | Smithkline Beecham Corporation | Anti-androgens and methods for treating disease |
| ATE245156T1 (de) * | 1999-03-11 | 2003-08-15 | Neurogen Corp | Aryl-annellierte disubstituierte pyridine : nk3 rezeptor-liganden |
| GB0027701D0 (en) | 2000-11-13 | 2000-12-27 | Smithkline Beecham Spa | Novel compounds |
| US20080194622A1 (en) | 2005-06-23 | 2008-08-14 | Astrazeneca Ab | Quinoline 3-Sulfonate Esters as Nk3 Receptor Modulators |
| MX2010001080A (es) | 2007-08-07 | 2010-03-01 | Hoffmann La Roche | Pirrolidin-aril-eteres como antagonistas de receptor de nk3. |
| KR101372743B1 (ko) | 2009-01-30 | 2014-03-14 | 에프. 호프만-라 로슈 아게 | Ｎｋ3 수용체 길항제로서 피페리딘 유도체 |
| US8318759B2 (en) | 2009-02-18 | 2012-11-27 | Hoffmann-La Roche Inc. | Pyrrolidine derivatives as NK3 receptor antagonists |
| AU2014255512A1 (en) * | 2013-04-19 | 2015-11-12 | Astrazeneca Ab | A NK3 receptor antagonist compound (NK3RA) for use in a method for the treatment of polycystic ovary syndrome (PCOS) |
-
2016
- 2016-10-19 WO PCT/IB2016/056271 patent/WO2017072629A1/en not_active Ceased
- 2016-10-26 AR ARP160103263A patent/AR106477A1/es unknown
- 2016-10-27 TW TW105134672A patent/TW201729808A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW201729808A (zh) | 2017-09-01 |
| WO2017072629A1 (en) | 2017-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2017004525A2 (es) | Dihidropirrolopiridinas inhibidoras de ror-gamma | |
| MX2021009673A (es) | Moduladores de ror-gamma. | |
| SV2017005461A (es) | Benzamidas sustituidas con 1,3-tiazol-2-ilo | |
| CL2018003429A1 (es) | Compuestos novedosos como inhibidores de la autotaxina y composiciones farmacéuticas que los comprenden. | |
| MX381639B (es) | Composicion oftalmica para el tratamiento de la enfermedad del ojo seco. | |
| MX2018003388A (es) | Agonistas del receptor farnesoide x y usos de los mismos. | |
| MX2016014308A (es) | Compuestos y composiciones como agonistas del receptor tipo toll 7. | |
| UY37098A (es) | Moduladores de ror-gamma | |
| DOP2016000208A (es) | Benzimidazol-2-aminas como inhibidores de midh1 | |
| MX2017002670A (es) | Inhibidores de glucosidasa. | |
| MX2023001193A (es) | Composicion de un anticuerpo inhibidor de masp-2 para usarse en el tratamiento de un padecimiento asociado con la activacion del complemento dependiente de masp-2. | |
| MX381640B (es) | Metodos y compuestos agonistas de gip. | |
| MX2017015838A (es) | Composiciones y metodos para tratar pterigion. | |
| MX382033B (es) | Compuestos heterocíclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma. | |
| MX2017014375A (es) | Moduladores del ccr2. | |
| ZA201906100B (en) | Combination of a ppar agonist with a fxr agonist | |
| CL2017001301A1 (es) | Composiciones oftálmicas estabilizadas de omega 3 | |
| CL2017000845A1 (es) | Inhibidores de gingipaina de lisina | |
| MX2018012285A (es) | Metodos de tratamiento para enfermedades colestasicas y fibroticas. | |
| AR110404A1 (es) | MÉTODOS PARA EL TRATAMIENTO DE ENFERMEDADES FIBRÓTICAS UTILIZANDO EL INTERFERÓN-l | |
| CO2017002312A2 (es) | Compuestos bicíclicos sustituidos | |
| CR20150653A (es) | Compuestos nuevos para el tratamiento del cáncer | |
| UY36732A (es) | Piridin pirazinonas novedosas como inhibidores de bromodominios de la familia bet | |
| AR106477A1 (es) | Combinación farmacéutica de antagonista del receptor nk3 y biguanidas | |
| MX2021005875A (es) | Composiciones y métodos para el tratamiento de trastornos neurodegenerativos, miodegenerativos y de almacenamiento lisosómico. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |